Literature DB >> 8496611

Role of CD25+ and CD25-T cells in acute HIV infection in vitro.

O Ramilo1, K D Bell, J W Uhr, E S Vitetta.   

Abstract

T cell activation plays a major role in the ability of the HIV to remain latent or establish a productive infection. The alpha-chain of the IL-2R (CD25, Tac, p55) is expressed on activated but not resting T cells and therefore represents an ideal marker to distinguish activated from resting T cells. The present studies were designed to define the role of CD25+ (activated) and CD25- (resting) T cells in an acute HIV infection in vitro. This objective was accomplished by selectively killing CD25+ cells with an anti-CD25-ricin A chain immunotoxin (RFT5-deglycosylated ricin A (dgA)) either before or after HIV infection, and then determining the effect of eliminating these cells on the secretion of viral p24 Ag. Three major findings have emerged from this study: 1) Elimination of the small population (3 to 5%) of activated, CD25+ cells present in normal PBMC before HIV infection results in a 99% reduction in p24 secretion. 2) RFT5-dgA, an immunotoxin directed against CD25, kills HIV-infected CD25+ cells. Elimination of the CD25+ cells after infection with HIV virtually stops viral production and the spread of the infection in these cultures. This was confirmed by coculturing RFT5-dgA-treated PBMC with H9 cells. 3) When RFT5-dgA-treated PBMC (CD25-cells) were infected with HIV and then activated with a solid phase anti-CD3 mAb, the levels of p24 produced were comparable with those of PBMC from which the CD25+ cells had not been eliminated. Taken together these findings suggest that both activated (CD25+) and resting/quiescent (CD25-) cells can be infected with HIV but that only the CD25+ cells produce viral proteins in the absence of additional activation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496611

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro.

Authors:  C McCoig; G Van Dyke; C S Chou; L J Picker; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 2.  Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.

Authors:  P De Paoli
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

Review 3.  Quiescent T cells and HIV: an unresolved relationship.

Authors:  Dimitrios N Vatakis; Christopher C Nixon; Jerome A Zack
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells.

Authors:  Dimitrios N Vatakis; Gregory Bristol; Thomas A Wilkinson; Samson A Chow; Jerome A Zack
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Highly purified CD25- resting T cells cannot be infected de novo with HIV-1.

Authors:  C S Chou; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

6.  Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency.

Authors:  S L Waldrop; C J Pitcher; D M Peterson; V C Maino; L J Picker
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

7.  Massive infection and loss of CD4+ T cells occurs in the intestinal tract of neonatal rhesus macaques in acute SIV infection.

Authors:  Xiaolei Wang; Terri Rasmussen; Bapi Pahar; Bhawna Poonia; Xavier Alvarez; Andrew A Lackner; Ronald S Veazey
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

8.  Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.

Authors:  Haitao Hu; Martin Nau; Phil Ehrenberg; Agnes-Laurence Chenine; Camila Macedo; Yu Zhou; Z John Daye; Zhi Wei; Maryanne Vahey; Nelson L Michael; Jerome H Kim; Mary Marovich; Silvia Ratto-Kim
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

9.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

10.  Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.

Authors:  Jesús Saavedra-Lozano; Cynthia C McCoig; Yanying Cao; Ellen S Vitetta; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.